



US00RE48404E

(19) **United States**
 (12) **Reissued Patent**
Kim et al.

(10) **Patent Number: US RE48,404 E**
 (45) **Date of Reissued Patent: *Jan. 26, 2021**

(54) **HYBRID HEPATOCYTE GROWTH FACTOR GENE HAVING HIGH EXPRESSION EFFICIENCY OF TWO HETEROTYPES OF HEPATOCYTE GROWTH FACTOR**

8,338,385 B2 * 12/2012 Kim A61P 1/16
 514/44 R
 8,389,492 B2 * 3/2013 Kim A61P 1/16
 514/44 R

(71) Applicant: **Helixmith Co., Ltd**, Seoul (KR)

(72) Inventors: **Jong-Mook Kim**, Seoul (KR); **Woong Hahn**, Goyang (KR); **Eun-Jin Park**, Seoul (KR)

(73) Assignee: **Helixmith Co., Ltd**, Seoul (KR)

(*) Notice: This patent is subject to a terminal disclaimer.

2002/0172663 A1 11/2002 Palasis
 2003/0148968 A1 8/2003 Hammond et al.
 2003/0171287 A1 9/2003 Morishita et al.
 2004/0105882 A1 6/2004 Morishita et al.
 2004/0228834 A1 11/2004 Isner et al.
 2005/0079581 A1 4/2005 Kim et al.
 2006/0286072 A1 12/2006 Giordano et al.
 2007/0059288 A1 3/2007 Dinsmore et al.
 2008/0268030 A1 10/2008 Morishita et al.
 2009/0004260 A1 1/2009 Morishita et al.
 2009/0082293 A1 3/2009 Giordano et al.
 2009/0131350 A1 5/2009 Kim et al.
 2009/0202606 A1 8/2009 Kim et al.
 2009/0258932 A1 10/2009 Kim et al.

(21) Appl. No.: **15/642,307**

(22) Filed: **Jul. 5, 2017**

Related U.S. Patent Documents

Reissue of:

(64) Patent No.: **7,745,174**
 Issued: **Jun. 29, 2010**
 Appl. No.: **12/650,860**
 Filed: **Dec. 31, 2009**

U.S. Applications:

(60) Division of application No. 10/944,277, filed on Sep. 20, 2004, now Pat. No. 7,812,146, which is a continuation of application No. PCT/KR03/00548, filed on Mar. 20, 2003.

(30) **Foreign Application Priority Data**

Mar. 20, 2002 (KR) 10-2002-0015074

(51) **Int. Cl.**
C07K 14/475 (2006.01)

(52) **U.S. Cl.**
 CPC **C07K 14/4753** (2013.01)

(58) **Field of Classification Search**
 CPC A61P 1/16; C07K 14/4753
 See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,328,836 A 7/1994 Shima et al.
 5,500,354 A 3/1996 Kitamura et al.
 5,580,859 A 12/1996 Felgner et al.
 5,587,359 A 12/1996 Higashio et al.
 5,652,225 A 7/1997 Isner
 5,693,622 A 12/1997 Wolff et al.
 6,013,624 A 1/2000 Goldberg et al.
 6,121,246 A 9/2000 Isner
 6,248,722 B1 6/2001 Morishita et al.
 6,258,787 B1 7/2001 Isner
 6,316,419 B1 11/2001 Leiden et al.
 6,413,942 B1 7/2002 Felgner et al.
 6,498,144 B1 12/2002 Goldberg et al.
 6,706,694 B1 3/2004 Wolff et al.
 6,887,477 B1 5/2005 Nagano et al.
 7,285,540 B2 10/2007 Morishita et al.
 7,745,174 B2 6/2010 Kim et al.
 7,812,146 B2 10/2010 Kim et al.
 7,838,505 B2 * 11/2010 Kim A61P 1/16
 514/44 R

FOREIGN PATENT DOCUMENTS

JP 11-246433 9/1999
 KR 2003-0075718 A 9/2003
 WO WO 98/50079 11/1998
 WO WO 98/50079 A2 11/1998
 WO WO 99/45775 9/1999
 WO WO 99/45775 A1 9/1999
 WO WO 01/34208 5/2001
 WO WO 01/34208 A1 5/2001

(Continued)

OTHER PUBLICATIONS

Folkman (Circulation. vol. 97, Issue 12, pp. 1108-1110). Mar. 31, 1998.*

Courtney et al. (GenBank Accession No. AC004960 available since Jun. 12, 1998, Retrieved from Internet: <http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucore&id=3845412>).

European Search Report for European Application No. EP 03 74 4561, dated Apr. 18, 2006, European Patent Office, Munich, Germany.

Office Action for U.S. Appl. No. 10/944,277, dated Jan. 9, 2008.
 Office Action for U.S. Appl. No. 10/944,277, dated Feb. 13, 2009.
 Notice of Allowance and Fees Due for U.S. Appl. No. 10/944,277, dated May 29, 2009.

Notice of Allowance and Fees Due for U.S. Appl. No. 10/944,277, dated Oct. 23, 2009.

Office Action for U.S. Appl. No. 11/957,170, dated Jan. 28, 2010.
 Esp@cenet Database, English language abstract of JP 11-246433 A, published Sep. 14, 1999 (listed as document B1 on the accompanying form PTO/SB/08A).

Romano et al. Stem Cells, 1999, 17 :191-202.

(Continued)

Primary Examiner — Padmashri Ponnaluri

(74) *Attorney, Agent, or Firm* — Fenwick & West LLP

(57) **ABSTRACT**

The present invention relates to a hybrid Hepatocyte Growth Factor (HGF) gene which is prepared by inserting an inherent or foreign intron between exons 4 and 5 in HGF cDNA, which has a base sequence of SEQ ID NO: 2. The gene has high expression efficiency and simultaneously expresses two heterotypes of HGF and dHGF (deleted variant HGF). Further the gene may be used for treating or preventing ischemic or liver diseases.

18 Claims, 12 Drawing Sheets

Specification includes a Sequence Listing.

(56)

References Cited

FOREIGN PATENT DOCUMENTS

WO WO 02/089856 11/2002
 WO WO 02/089856 A1 11/2002

OTHER PUBLICATIONS

Liu et al, *Journal of Controlled Release* vol. 78, Issues 1-3, Jan. 17, 2002, pp. 259-266.

Schmitz et al, *Gut*, Jan. 2002; 50(1): 130-135.

U.S. Appl. No. 12/650,860, inventors Kim et al., filed Dec. 31, 2009. Notice of Allowance and Fees Due for U.S. Appl. No. 12/650,860, dated Mar. 10, 2010.

Gardilik, et al., "Vectors and delivery systems in gene therapy," *Med Sci Monit* 11(4):RA110-121 (2005).

Kato et al., "Nonviral HVJ (hemagglutinating virus of Japan) liposome-mediated retrograde gene transfer of human hepatocyte growth factor into rat nervous system promotes functional and histological recovery of the crushed nerve," *Neuroscience Research*, 52, pp. 299-310, Elsevier Ireland Ltd and the Japan Neuroscience Society (2005).

Patil, et al., "DNA-based Therapeutics and DNA Delivery Systems: A Comprehensive Review," *The AAPS Journal* 9(1) Article 9:E61-E77 (2005).

Thomas, et al., "Progress and Problems with the use of viral vectors for gene therapy," *Nature Reviews Genetics* 4:346-358, Nature Publishing Group (2003).

Yang, et al., "Sustained Expression of Naked Plasmid DNA Encoding Hepatocyte Growth Factor in Mice Promotes Liver and Overall Body Growth," *Hepatology* 33:848-859, American Assoc. for the Study of Liver Disease (2001).

Notice of Allowance for U.S. Appl. No. 11/957,170 (now U.S. Pat. No. 7,838,505), dated Jul. 19, 2010.

Office Action for U.S. Appl. No. 12/359,137, dated Apr. 28, 2011.

Office Action for U.S. Appl. No. 12/421,425, dated Aug. 19, 2010.

Office Action for U.S. Appl. No. 12/421,425, dated Dec. 17, 2010.

U.S. Appl. No. 13/045,460, filed Mar. 10, 2011.

File History of U.S. Appl. No. 12/650,860, filed Dec. 31, 2009, Inventors: Jong-Mook Kim et al.

File History of U.S. Appl. No. 11/957,170, filed Dec. 14, 2007, Inventors: Jong-Mook Kim et al.

File History of U.S. Appl. No. 10/944,277, filed Sep. 20, 2004, Inventors: Jong-Mook Kim et al.

File History of U.S. Appl. No. 12/908,765, filed Oct. 20, 2010, Inventors: Jong-Mook Kim et al.

PCT International Search Report, PCT Application No. PCT/KR2003/000548, Sep. 5, 2003, 3 pages.

Shi, E. et al., "Nonviral Gene Transfer of Hepatocyte Growth Factor Attenuates Neurologic Injury After Spinal Cord Ischemia in Rabbits," *Cardiopulmonary Support and Physiology, The Journal of Thoracic and Cardiovascular Surgery*, Oct. 2006, pp. 941-947, vol. 132, No. 4.

Morishita, R. et al., "Safety Evaluation of Clinical Gene Therapy Using Hepatocyte Growth Factor to Treat Peripheral Arterial Disease," *Hypertension*, Aug. 2004, 13 pages.

Shigematsu, H. et al., "Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Hepatocyte Growth Factor Plasmid for Critical Limb Ischemia," *Gene Therapy*, 2010, pp. 1152-1161, vol. 17.

Kibbe, M.R. et al., "Safety and Efficacy of Plasmid DNA Expressing Two Isoforms of Hepatocyte Growth Factor in Patients with Critical Limb Ischemia," *Gene Therapy*, 2016, pp. 306-312, vol. 23.

Henry, T.D. et al., "Safety of a Non-Viral Plasmid-Encoding Dual Isoforms of Hepatocyte Growth Factor in Critical Limb Ischemia Patients: A Phase I Study," *Gene Therapy*, 2011, pp. 788-794, vol. 18.

Deng, et al., "Secretory Expression of the Deleted Variant of Human Hepatocyte Growth Factor (hdHGF) in *Pichia pastoris*," *Chinese Journal of Biochemistry and Molecular Biology*, 2001, 17:590-594, China Academic Journal Electronic Publishing House, Beijing, China.

Kisselev, L., "Polypeptide Release Factors in Prokaryotes and Eukaryotes: Same Function, Different Structure," *Structure*, 2002, 10, pp. 8-9, Elsevier Science Ltd., Cambridge, Massachusetts, USA.

Liu, Y., "The human hepatocyte growth factor receptor gene: complete structural organization and promoter characterization," *Gene* 215:159-169, Elsevier/North-Holland (1998).

Miyazawa, K., et al., "Molecular Cloning and Sequence Analysis of cDNA for Human Hepatocyte Growth Factor," *Biochem. Biophys. Res. Commun.* 163:967-973, Academic Press (1989).

Nakamura, T., et al., "Molecular cloning and expression of human hepatocyte growth factor," *Nature* 342:440-443, Nature Publishing Group (1989).

NCBI Entrez, GenBank Database, Accession No. AC004960, "*Homo sapiens* PAC clone RP5-1098B1 from 7q11.23-q21, complete sequence," 51 pages (first available 1998).

Ngo et al., In *The Protein Folding Problem and Tertiary Structure Prediction*, 1994, Merz et al. (ed.), Birkhauser, Boston, MA, pp. 433 and 492-495.

Potrykus. Gene transfer to cereals: an assessment, *Biotechnology*, 1990, 8(6):535-542.

Rubin, et al., "A broad-spectrum human lung fibroblast-derived mitogen is a variant of hepatocyte growth factor," *Proc. Natl. Acad. Sci. USA*, 1991, 88:415-419, Proceedings of the National Academy of Sciences of the United States of America, 500 5th St., Washington, DC 20001.

Seki, T., et al., "Isolation and Expression of cDNA for Different Forms of Hepatocyte Growth Factor from Human Leukocyte," *Biochem. Biophys. Res. Commun.* 172:321-327, Academic Press (1990).

Seki, T., et al., "Organization of the human hepatocyte growth factor-encoding gene," *Gene* 102:213-219, Elsevier/North-Holland (1991).

Shima, N., et al., "Hepatocyte Growth Factor and its Variant with a Deletion of Five Amino Acids are Distinguishable in their Biological Activity and Tertiary Structure," *Biochem. Biophys. Res. Commun.* 200:808-815, Academic Press (1994).

Warnecke C. et al., "Efficient transcription of the human angiotensin II type 2 receptor gene requires intronic sequence elements," *Biochemical journal*, 1999, 340 (1), pp. 17-24, Portland Press, Colchester, Great Britain.

Wishart et al., "A Single Mutation Converts a Novel Phosphotyrosine Binding into a Dual-Specificity Phosphatase," *Journal of Biological Chemistry*, 1995, 270 (45), pp. 26782-26785, American Society for Biochemistry and Molecular Biology, Bethesda, MD, USA.

Witkowski et al., "Conversion of a A-Ketoacyl Synthase to a Malonyl Decarboxylase by Replacement of the Active-Site Cysteine with Glutamine," *Biochemistry*, 1999, 38 (36), pp. 11643-11650, American Chemical Society, Washington, DC, USA.

Office Action for Co-pending U.S. Appl. No. 10/944,277, mailed Jan. 9, 2008.

Office Action for Co-Pending U.S. Appl. No. 10/944,277, mailed Feb. 13, 2009.

Notice of Allowance and Fees Due for Co-Pending U.S. Appl. No. 10/944,277, mailed May 29, 2009.

Notice of Allowance and Fees Due for Co-Pending U.S. Appl. No. 10/944,277, mailed Oct. 23, 2009.

Office Action for Co-pending U.S. Appl. No. 11/957,170, mailed Jan. 28, 2010.

* cited by examiner




FIG. 2






FIG. 3








FIG. 5




FIG. 6




FIG. 7




FIG. 8




FIG. 9





FIG. 10






FIG. 11

**HYBRID HEPATOCYTE GROWTH FACTOR
GENE HAVING HIGH EXPRESSION
EFFICIENCY OF TWO HETEROTYPES OF
HEPATOCYTE GROWTH FACTOR**

Matter enclosed in heavy brackets [] appears in the original patent but forms no part of this reissue specification; matter printed in italics indicates the additions made by reissue; a claim printed with strikethrough indicates that the claim was canceled, disclaimed, or held invalid by a prior post-patent action or proceeding.

[This application is a continuation] *The present application is a Reissue of U.S. Pat. No. 7,745,174, which issued on Jun. 29, 2010 from application Ser. No. 12/650,860, filed Dec. 31, 2009. U.S. application Ser. No. 12/650,860 is a divisional of U.S. application Ser. No. 10/944,277, filed Sep. 20, 2004, now U.S. Pat. No. 7,812,146, which is a continuation of International Application No. PCT/KR03/00548, filed Mar. 20, 2003, which claims priority benefit to Korean Appl. No. 10-2002-0015074, filed Mar. 20, 2002, each of which [are] is herein incorporated by reference in [their] its entirety.*

REFERENCE TO A SEQUENCE LISTING
SUBMITTED ELECTRONICALLY

The content of the electronically submitted sequence listing ("sequencelisting.ascii.txt", 29,879 bytes, created on Dec. 30, 2009) filed with the application is incorporated herein by reference in its entirety.

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention relates to a highly efficient hybrid Hepatocyte Growth Factor (HGF) gene which simultaneously expresses two heterotypes of HGF.

2. Related Art

The present invention relates to a hybrid HGF gene prepared by inserting an inherent or foreign intron between exons 4 and 5 in HGF cDNA, which has higher expression efficiency than HGF cDNA and simultaneously expresses two heterotypes of HGF and dHGF (deleted variant HGF).

HGF is a heparin binding glycoprotein called a scatter factor. A gene encoding HGF is located at chromosome [721.1] 7q21.1 and comprises 18 exons and 17 introns, having the nucleotide sequence of SEQ ID NO: 1 (Seki T., et al., Gene 102:213-219 (1991)). A transcript of about 6 kb is transcribed from the HGF gene, and then, a polypeptide HGF precursor consisting of 728 amino acids is synthesized therefrom. Simultaneously, a polypeptide of dHGF precursor consisting of 723 amino acids is also synthesized by an alternative splicing of the HGF gene. The biologically inactive precursors may be converted into active forms of disulfide-linked heterodimer by protease in serum. In the heterodimers, the alpha chain having a high molecular weight forms four kringle domains and an N-terminal hairpin loop like a preactivated peptide region of plasminogen. The kringle domains of a triple disulfide-bonded loop structure consisting of about 80 amino acids may play an important role in protein-protein interaction. The low molecular weight beta chain forms an inactive serine protease-like domain. dHGF consisting of 723 amino acids is a polypeptide

with deletion of five amino acids in the 1st kringle domain of the alpha chain, i.e., F, L, P, S and S.

It has been recently reported that both of HGF and dHGF have several biological functions, e.g., promoting the growth and morphogenesis of epithelial cell, melanocyte and endothelial cell. However, they are different in terms of immunological or biological properties.

For example, HGF shows about 20-fold, 10-fold and 2-fold higher activities than dHGF in promoting DNA synthesis in human umbilical cord venous endothelial cell, arterial smooth muscle cell and NSF-60 (murine myeloblast cell), respectively. dHGF shows about 3-fold and 2-fold higher activities than HGF in promoting DNA synthesis of LLC-PK1 (pig kidney epithelial cell), and OK (American opossum kidney epithelial cell) and mouse interstitial cell, respectively. HGF has a 70-fold higher solubility in PBS than dHGF. Several anti-dHGF monoclonal antibodies recognize only dHGF, but not HGF or a reduced form of dHGF, which implies structures of HGF and dHGF are different. Accordingly, the simultaneous synthesis of HGF and dHGF in vivo suggests that they biologically interact with each other (Shima, N. et al., Biochemical and Biophysical Research Communications 200:808-815 (1994)).

HGF secreted from mesoderm-derived cells has various biological functions, e.g., 1) inducing epithelial cells into a tubular structure; 2) stimulating vascularization from endothelial cells in vitro and in vivo; 3) regeneration of liver and kidney, owing to its anti-apoptosis activity; 4) organogenesis of kidney, ovary and testis; 5) controlling osteogenesis; 6) stimulating the growth and differentiation of erythroid hematopoietic precursor cells; and 7) axon sprouting of neurons (Stella, M. C. and Comoglio, P. M., The International Journal of Biochemistry & Cell Biology 31:1357-1362 (1999)). Based on these various functions, HGF or a gene encoding HGF may be developed as a therapeutic agent for treating ischemic or liver diseases. Actually, in vivo, the HGF may exist as either HGF or dHGF, and therefore, the coexpression of HGF and dHGF is important for maximizing the therapeutic effect. Accordingly, the present inventors have endeavored to develop a hybrid HGF gene which can simultaneously express HGF and dHGF with a high efficiency for gene therapy.

SUMMARY OF THE INVENTION

Accordingly, it is a primary object of the present invention to provide a hybrid HGF gene which simultaneously expresses two heterotypes of HGF.

In accordance with one aspect of the present invention, there is provide the hybrid HGF gene having an inherent or foreign intron is inserted between exons 4 and 5 of HGF cDNA.

It is a another object of the present invention to provide a recombinant vector comprising the hybrid HGF gene and a microorganism transformed with the above vector.

It is a still further object of the present invention to provide a pharmaceutical composition for treating or preventing ischemic or liver diseases, which comprises the HGF gene.

BRIEF DESCRIPTION OF THE DRAWINGS

The above and other objects and features of the present invention will become apparent from the following description of the invention, when taken in conjunction with the accompanying drawings which respectively show:

3

FIG. 1: a schematic diagram of HGF-X prototype illustrating the positions of the gene fragments,

FIG. 2: a process for cloning gene fragments from HepG2 genomic DNA,

FIG. 3: a process for cloning gene fragments from human placenta cDNA,

FIGS. 4A and 4B: processes for preparing expression vectors pCK-HGF-X,

FIG. 5: a process for preparing expression vectors pCK-cHGF and pCK-dHGF,

FIG. 6: a process for preparing expression vectors pCP-HGF-X family,

FIG. 7: a process for preparing expression vectors pCP-cHGF and pCP-dHGF,

FIG. 8: gene expression levels of pCP-cHGF, pCP-dHGF and pCP-HGF-X.

FIG. 9: gene expression patterns of pCP-cHGF, pCP-dHGF and pCP-HGF-X observed by electrophoresis on 12% polyacrylamide gel,

FIG. 10: gene expression levels of pCP-cHGF, pCP-dHGF and pCP-HGF-X7, in vivo,

FIG. 11: cerebral angiogenesis of two groups of rabbits which were subject to administering pCP and pCP-HGF-X7, respectively,

DETAILED DESCRIPTION OF THE INVENTION

The hybrid Hepatocyte Growth Factor (HGF) gene of the present invention comprises cDNA corresponding to the exons 1 to 18, and an inherent or foreign intron inserted between exons 4 and 5 of the cDNA. The intron comprises a fragment of the inherent intron or a recombinant sequence.

An embodiment of the hybrid HGF gene of the present invention comprising the inherent intron is 7113 bp long and has the nucleotide sequence of SEQ ID NO: 2. The hybrid HGF gene simultaneously expresses both HGF and dHGF, and has higher expression efficiency than HGF cDNA.

Codon degeneracy enables the hybrid HGF gene of the present invention to be modified or changed in the coding and/or non-coding region without altering the amino acid sequence of the protein and the expression of the gene. Accordingly, polynucleotides which is substantially identical to the hybrid HGF gene of SEQ ID NO:2, and the fragments thereof fall within the scope of the invention. "Substantially identical" means that the sequence homology is not less than 80%, preferably not less than 90%, and more preferably not less than 95%.

A hybrid HGF gene may comprise a fragment of inherent intron optionally having a small recombinant sequence inserted therein between exons 4 and 5 of HGF cDNA. Herein, such a hybrid HGF gene comprising a fragment of inherent intron designates "HGF-X". HGF-X6, HGF-X7 and HGF-X8 having the nucleotide sequence of SEQ ID Nos: 19 to 21, respectively, are preferred.

The hybrid HGF gene of the present invention is synthesized and inserted into an expression vector, according to the known genetic engineering methods. Then, the vector can be introduced into an appropriate host cells such as *E. coli* and yeast. For example, *Escherichia coli* Top10F' may be transfected with HGF-X7 gene of the present invention. *Escherichia coli* Top10F' pCK-HGFX7 and *Escherichia coli* Top10F' pCP-HGFX7 then obtained were deposited as the accession numbers KCCM-10361 and KCCM-10362, respectively, on Mar. 12, 2002.

4

By using the transformed cells, the gene of the present invention and the protein encoded thereby may be produced on a large scale.

The vector of the present invention may selectively comprise sequence(s) for regulating gene expression such as promoter or terminator, self-replication sequence and secretory signal, depending on host cells.

Further, the present invention comprises a pharmaceutical composition for treating or preventing ischemic and liver diseases, which comprises the hybrid HGF gene or the vector comprising the gene as an active ingredient. Preferably, the composition is formulated for injection.

The composition of the present invention may further comprise pharmaceutically acceptable carriers. Any of the conventional procedures in the pharmaceutical field may be used to prepare oral formulations such as tablets, capsules, pills, granules, suspensions and solutions; injection formulations such as solutions, suspensions, or dried powders that may be mixed with distilled water before injection; locally-applicable formulations such as ointments, creams and lotions; and other formulations.

Carriers generally used in the pharmaceutical field may be employed in the composition of the present invention. For example, orally-administered formulations may include binders, emulsifiers, disintegrating agents, excipients, solubilizing agents, dispersing agents, stabilizing agents, suspending agents, coloring agents or spicery. Injection formulations may comprise preservatives, unagonizing agents, solubilizing agents or stabilizing agents. Preparation for local administration may contain bases, excipients, lubricants or preservatives. Any of the suitable formulations known in the art (Remington's Pharmaceutical Science [the new edition], Mack Publishing Company, Eaton Pa.) may be used in the present invention.

The inventive composition can be clinically administered as various oral and parenteral formulations. A suitable formulation may be prepared using such excipients as additives, enhancers, binders, wetting agents, disintegrating agents and surfactants, or diluents. Solid formulations for oral administration include pills, tablets, dusting powder, granules and capsules. Those solid formulations may be prepared by mixing one or more excipients, e.g. starch, calcium carbonate, sucrose, lactose and gelatin with dibenzylbutylacton lignan derivatives. Also, lubricants such as magnesium stearate and talc may be included in the present formulation. Liquid formulations for oral administration include suspension, solution, emulsion and syrup. Those formulations may contain wetting agents, sweeteners, aromatics and preservatives, in addition to general simple diluents such as water and liquid paraffin. Formulations for parenteral administration include sterilized aqueous solution, suspension, emulsion, freeze-dried alternative treatment and suppositories. Water-insoluble excipients and suspending agents comprise vegetable fats such as propylene glycol, polyethylene glycol and olive oil, and injectable esters such as ethyl oleate. Witepsol®, Macrogol®, Tween® 61, cacao fats, laurin fats and glycerogelatins may be used as bases of suppositories.

The inventive composition may be administered orally or via parenteral routes such as intravenous, intramuscular, subcutaneous, intraabdominal, sternal and arterial injection or infusion, or topically through rectal, intranasal, inhalational or intraocular administration.

It should be understood that the typical daily dose of composition of the present invention ought to be determined in light of various relevant factors including the conditions to be treated, the chosen route of administration, the age, sex

5

and body weight of the individual patient, and the severity of the patient's symptom, and can be administered in a single dose or in divided dose. Therefore, the daily dose should not be construed as a limitation to the scope of the invention in any way.

The following Examples are given for the purpose of illustration only, and are not intended to limit the scope of the invention.

EXAMPLE 1

Preparation of Hybrid Gene Constructs Encoding Human HGF

(1) Cloning of HGF Gene Fragments Obtained from Genomic DNA

Human HepG2 cells (ATCC Accession NO: HB-8065) were suspended in TES buffer (10 mM Tris-HCl; 1 mM EDTA; 0.7% SDS) and treated with 400 µg/ml of proteinase K at 50° C. for 1 hour. Subsequently, genomic DNA was extracted from the cell suspension by phenol/chloroform extraction and ethanol precipitation according to the conventional method in the art.

In the PCR amplification, the extracted genomic DNA was employed as a template DNA. As primer pairs, the synthetic nucleotides of SEQ ID NOs: 3 and 4 were employed to obtain DNA fragments containing: HGF gene fragment 2 (HGF-F2), SEQ ID NOs: 3 and 5; HGF-F3, SEQ ID NOs: 6 and 7; HGF-F5, SEQ ID NOs: 8 and 7; HGF-F7, SEQ ID NOs: 9 and 7; HGF-F8, SEQ ID NOs: 10 and 7; HGF-F6, respectively (FIG. 1). The PCR amplification mixture was prepared by mixing 1 µl of template DNA, 1 µl each of primer (10 pmol/µl), 10 µl of dNTP (10 mM), 3.5 unit of Expand High Fidelity enzyme (Gibco BRL, USA) and 10 µl of enzyme buffer solution and adjusted to a final volume of 100 µl with distilled water. 30 cycles of the PCR amplification was carried out, each cycle consisting of 1 min at 94° C., 1 min at 55° C. and 30 sec at 72° C. The primers used herein and the amplified gene fragments obtained therefrom are shown in Table 1.

TABLE 1

5' primer	3' primer	Amplified fragment
gHGF3 (SEQ ID NO: 3)	gHGF4 (SEQ ID NO: 4)	HGF gene fragment 2 (HGF-F2)
gHGF3 (SEQ ID NO: 3)	gHGF10 (SEQ ID NO: 5)	HGF gene fragment 3 (HGF-F3)
gHGF5 (SEQ ID NO: 6)	gHGF7 (SEQ ID NO: 7)	HGF gene fragment 5 (HGF-F5)
gHGF12 (SEQ ID NO: 8)	gHGF7 (SEQ ID NO: 7)	HGF gene fragment 7 (HGF-F7)
gHGF13 (SEQ ID NO: 9)	gHGF7 (SEQ ID NO: 7)	HGF gene fragment 8 (HGF-F8)
gHGF6 (SEQ ID NO: 10)	gHGF7 (SEQ ID NO: 7)	HGF gene fragment 6 (HGF-F6)

The amplified HGF-F2 comprised the sequence ranging from 392 to 2247 of human HGF cDNA prototype (HGF-X1; composed of exons 1 to 4-intron 4-exons 5 to 18) of SEQ ID NO: 2; HGF-F3, the sequence ranging from 392 to 727; HGF-F5, the sequence ranging from 2229 to 5471; HGF-F6, the sequence ranging from 5117 to 5471; HGF-F7, the sequence ranging from 3168 to 5471; and HGF-F8, the sequence ranging from 4168 to 5471.

The amplified HGF gene fragments were each inserted into the multiple cloning site of pGEM-T easy vector (Promega, WI, USA) to obtain pGEM-T easy-HGF-F2,

6

pGEM-T easy-HGF-F3, pGEM-T easy-HGF-F5, pGEM-T easy-HGF-F6, pGEM-T easy-HGF-F7 and pGEM-T easy-HGF-F8, respectively (FIG. 2). The nucleotide sequences of the amplified HGF gene fragments were confirmed by a sequence analysis.

(2) Cloning of HGF Gene Fragments Obtained from cDNA

In the PCR amplification, human placenta cDNA (Clontech, CA, USA) was employed as a template DNA under the same condition as described in Example 1. As primer pairs, the synthetic oligonucleotides of SEQ ID NOs: 11 and 12, and SEQ ID NOs: 13 and 14 were employed to obtain DNA fragments containing HGF-F1 and HGF-F4, respectively. Further, DNA fragments containing cDNAs of HGF gene (cHGF) and deleted HGF gene (dHGF) were amplified by PCR using synthetic oligonucleotides of SEQ ID NOs: 15 and 16 as a primer pair, respectively. dHGF is a HGF gene with deletion of 5 base sequences.

The primers used herein and the amplified gene fragments obtained therefrom are shown in Table 2.

TABLE 2

5' primer	3' primer	Amplified fragment
gHGF1 (SEQ ID NO: 11)	gHGF2 (SEQ ID NO: 12)	HGF gene fragment 1 (HGF-F1)
gHGF8 (SEQ ID NO: 13)	gHGF9 (SEQ ID NO: 14)	HGF gene fragment 4 (HGF-F4)
cHGF5 (SEQ ID NO: 15)	cHGF3 (SEQ ID NO: 16)	HGF gene cDNA (cHGF)
		dHGF gene cDNA (dHGF)

The amplified HGF-F1 and HGF-F4 comprised the nucleotide sequences ranging from 1 to 402 and from 6533 to 7113 of SEQ ID NO: 2 of human HGF cDNA prototype, respectively. HGF gene cDNA comprised the nucleotide sequence ranging from 1 to 2184 of SEQ ID NO: 1 of human HGF gene, and dHGF gene cDNA has the same sequence as HGF gene cDNA except for the deletion of the sequence ranging from 483 to 495.

The amplified fragments of HGF gene were each inserted into the multiple cloning site of pGEM-T easy vector (Promega, WI, USA) to obtain pGEM-T easy-HGF-F1, pGEM-T easy-HGF-F4, pGEM-T easy-cHGF and pGEM-T easy-dHGF, respectively (FIG. 3). The nucleotide sequences of the human HGF gene fragments, HGF gene cDNA and dHGF gene cDNA were confirmed by sequence analyses.

(3) Preparation of Hybrid HGF Gene Constructs

Hybrid HGF gene constructs of genomic DNA and cDNA were prepared by combining the fragments of HGF gene cloned in steps (1) and (2) as follows (FIGS. 4A and 4B).

Plasmid pGEM-T-easy-HGF-F1 was treated with HindIII/BamHI to obtain HGF-F1. Plasmid pCK (see PCT International Publication NO: WO/0040737) was treated with HindIII/BamHI, and HGF-F1 was inserted thereinto to obtain pCK-F1. And then, plasmids pGEM-T-easy-HGF-F2 and pGEM-T-easy-HGF-F3 were treated with MluI/BamHI to obtain HGF-F2 and HGF-F3, respectively. pCK-1 was treated with MluI/BamHI, and then HGF-F2 and HGF-F3 were inserted thereinto to obtain pCK-F12M and pCK-F13M. The MluI restriction site of vectors pCK-F12M and pCK-F13M was substituted with an HgaI restriction site by employing a site-directed mutagenesis kit (Stratagene, CA., USA) to obtain pCK-F12 and pCK-F13, respectively.

Further, plasmid pGEM-T-easy-HGF-F4 was treated with BamHI/XbaI to obtain HGF-F4. pCK-F12 and pCK-F13 were treated with BamHI/XbaI, and HGF-F4 was inserted

thereinto to obtain pCK-F124 and pCK-F134, respectively. And then, plasmids pGEM-T-easy-HGF-F5, pGEM-T-easy-HGF-F6, pGEM-T-easy-HGF-F7 and pGEM-T-easy-HGF-F8 were treated with BamHI/XhoI to obtain HGF-F5, HGF-F6, HGF-F7 and HGF-F8, respectively. pCK-F124 and pCK-F134 were treated with BamHI/XhoI, and then HGF-F5, HGF-F6, HGF-F7 and HGF-F8 were inserted thereinto to obtain pCK-F1254 and pCK-F1264, pCK-F1274, pCK-F1284, pCK-F1354, pCK-F1364, pCK-F1374 and pCK-F1384, respectively.

And then, pGEM-T easy-cHGF was treated with XhoI to obtain cDNA fragment of HGF gene (HGF-XhoI) of about 1100 bp. Then, HGF-XhoI was inserted into pCK-F1254, pCK-F1264, pCK-F1274, pCK-F1284, pCK-F1354, pCK-F1364, pCK-F1374 and pCK-F1384 to obtain pCK-HGF-X1, pCK-HGF-X2, pCK-HGF-X3, pCK-HGF-X4, pCK-HGF-X5, pCK-HGF-X6, pCK-HGF-X7 and pCK-HGF-X8, respectively. On the other hand, pGEM-T easy-cHGF and pGEM-T easy-dHGF were treated with BamHI to obtain HGF gene cDNA and dHGF gene cDNA. Then, HGF gene cDNA and dHGF gene cDNA were inserted into the BamHI restriction site of pCK to obtain pCK-cHGF and pCK-dHGF, respectively (FIG. 5).

(4) Preparation of an Expression Vector Containing a Hybrid HGF Gene Construct

Plasmid pcDNA3.1 (Invitrogen, USA) was digested with NdeI, treated with the Klenow fragment to build blunt ends, and then digested with NheI to obtain a DNA fragment containing human cytomegalovirus promoter. Plasmids pCK-HGF-X1, pCK-HGF-X2, pCK-HGF-X3, pCK-HGF-X4, pCK-HGF-X5, pCK-HGF-X6, pCK-HGF-X7 and pCK-HGF-X8 were digested with SnaBI, treated with the Klenow fragment to make blunt ends and digested with NheI, and then the above DNA fragment containing human cytomegalovirus promoter was inserted thereinto to obtain pCP-HGF-X1, pCP-HGF-X2, pCP-HGF-X3, pCP-HGF-X4, pCP-HGF-X5, pCP-HGF-X6, pCP-HGF-X7 and pCP-HGF-X8, respectively (FIG. 6).

Plasmid pcDNA3.1 (Invitrogen, USA) was digested with NheI, treated with the Klenow fragment to make blunt ends and digested with NdeI to obtain the DNA fragment containing human cytomegalovirus promoter. pCK-cHGF and pCK-dHGF were digested with MluI, treated with the Klenow fragment to make blunt ends and digested with NdeI, and then the above DNA fragment containing human cytomegalovirus promoter was inserted thereinto to obtain pCP-cHGF and pCP-dHGF, respectively (FIG. 7).

EXAMPLE 2

Examination of the Expression Efficiency of Hybrid HGF Gene Construct and the Coexpression of HGF/dHGF

Studies was conducted to examine whether the hybrid HGF gene constructs (HGF-X1 to HGF-X8) obtained in Example 1 can simultaneously express HGF and dHGF and whether there is any difference in the gene expression level between hybrid HGF gene constructs and HGF cDNA.

(1) Gene Expression Efficiency

First, 5 μ g of pCP-HGF-X2, pCP-HGF-X3, pCP-HGF-X6, pCP-HGF-X7 and pCP-HGF-X8 were transfected into 5×10^6 cells of 293 cell (ATCC CRL 1573) together with 0.5 μ g of DONAI-LacZ (TAKARA SHUZO, Japan) DNA using FuGENE6 (Gibco BRL, MD, USA), according to the manufacturer's instructions. At this time, 5 μ g each of pCP-cHGF and pCP-dHGF were used as controls, and DONAI-LacZ

DNA was used to calibrate the infection efficiency. 3 hours after transfection, cells were re-fed with a fresh medium and further cultured for 48 hours. The culture solution thus obtained was divided into two parts. One part of the 293 cell culture solution was subjected to RNA extraction, and the other, to measurement of LacZ activity. The LacZ activity was measured using an activity measuring kit (Stratagene, CA, USA) according to the manufacturer's instructions.

In order to compare the gene expression levels, the amount of HGF in the cell culture was measured by an enzyme-linked immunosorbent assay kit (ELISA, R&D System, MN, USA). After calibrating the infection efficiency by the measured LacZ activity, the expression level of HGF-X gene was found to be from 20 to 150-fold higher than those of HGF cDNA and dHGF cDNA (FIG. 8). HGF-X7, in particular, showed the highest gene expression level.

(2) Coexpression of HGF and dHGF

In order to examine coexpression of HGF and dHGF from hybrid HGF gene constructs, total cellular RNAs were extracted from the transfected 293 cells using the Trizol method (Trizol; Gibco BRL, USA) and subjected to RT-PCR to obtain cDNA. Then, using cDNA as a template DNA, PCR amplification was carried out using synthetic oligonucleotides of SEQ ID NOS: 17 and 18 as a primer pair. The PCR amplification mixture was prepared by mixing 1 μ l of the template DNA, 1 μ l each of the primer (10 pmol/ μ l), 10 μ l of dNTP (10 mM), 3.5 unit of Taq polymerase (TAKARA SHUZO, Japan) and 10 μ l of enzyme buffer solution and adjusted to a final volume of 100 μ l with distilled water. 30 cycles of PCR amplification was conducted, each cycle consisting of 1 min at 94° C., 1 min at 55° C., and 90 sec at 72° C.

The amplified PCR products corresponded to the boundary region between exons 4 and 5 of HGF gene; HGF gene cDNA of 142 by and dHGF gene cDNA of 127 bp, respectively. With no splicing, the PCR product of at least 1 kb in length was amplified; and if alternative splicing occurred, HGF gene cDNA of 142 bp and dHGF gene cDNA of 127 by were simultaneously synthesized and amplified. The amplified PCR products were distinguished by electrophoresis on a 12% polyacrylamide gel.

As shown in FIG. 9, while the bands of 142 by and 127 by were detected in the lanes loading HGF gene cDNA and dHGF gene cDNA, respectively, both bands of 142 by and 127 by were detected in the lanes loading HGF-X. The above results suggest that HGF and dHGF are simultaneously expressed from hybrid HGF-X gene constructs of the present invention.

EXAMPLE 3

Comparison of Expression Levels of HGF-X7, HGF Gene cDNA and dHGF Gene cDNA (In Vivo)

100 μ g each of pCP-HGF-X7, pCP-cHGF and pCP-dHGF were injected into the [anterior] anterior tibial muscle of the hind limb of mice with an insulin syringe. After 5 days, the mice were sacrificed and the muscles around the injection spot were removed and smashed in a protein extraction buffer (25 mM Tris-HCl (pH 7.4), 50 mM NaCl, 0.5% Na-deoxycholate, 2% NP-40, 0.2% SDS) to separate total proteins. The amount of the total proteins was measured with a DC protein analysis kit (Bio-Rad Laboratories, CA,

USA) and the amount of expressed HGF was determined with an ELISA kit (R&D System) according to the manufacturer's instruction.

As can be seen from the result shown in FIG. 10, the amount of HGF expressed from HGF-X7 is 250-fold higher than that from HGF gene cDNA or dHGF gene cDNA.

Together with the result of the experiment of Example 2 (in vivo), this result demonstrates that the expression efficiency of HGF-X gene is much superior to those of HGF gene cDNA or dHGF gene cDNA.

EXAMPLE 4

Gene Therapy Employing HGF-X7 in a Rabbit Ischemic Hind Limb Model

In order to examine whether HGF-X7 gene is effective in the treatment of ischemic hind limb disease, gene therapy was carried out on a rabbit ischemic hind limb model as follows.

A rabbit ischemic hind limb model, which is a standard animal model for the ischemic limb disease, was prepared by the method described by Takeshita et al., Journal of Clinical Investigation 93:662 (1994). At the day before operation (day 0), each of 30 white rabbits from New Zealand (male, from 3.8 to 4.2 kg) was intramuscularly injected with 5 mg/kg of xylazine and, then, anesthetized by an intramuscular injection of 50 mg/kg of ketamine. Subsequently, the

left femoral region of the rabbit was incised and all branches of the femoral artery were separated and tied. The region from the proximal part to the branching point of the saphenous and popliteal arteries was incised to prepare the model. After the operation, 15 mg/kg/day of cefazolin was injected intramuscularly for 5 days and 0.3 mg/day of morphine, for 10 days. 10 days after the operation (day 10), angiography was carried out for the left hind limb where the ischemia was induced, and the degree of arteriogenesis was recorded as a basal level. The rabbits were randomly divided into two groups and injected at four sites in the femoral muscle with 500 µg of plasmid pCP-HGF-X7 (experimental group) or 500 µg of plasmid pCP (control), respectively. 40 days after the operation (day 40), angiography was carried out again for the left hind limb and the degree of arteriogenesis at the arteriole level was determined and compared to that of day 10.

As can be seen from the result in FIG. 11, the degree of angiogenesis was significantly enhanced in the experimental group administered with pCP-HGF-X7 as compared with the pCP-administered control group.

This result demonstrates that HGF-X7 gene can be effectively used in the gene therapy of an ischemic disease.

While the invention has been described with respect to the above specific embodiments, it should be recognized that various modifications and changes may be made to the invention by those skilled in the art which also fall within the scope of the invention as defined by the appended claims.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 21

<210> SEQ ID NO 1

<211> LENGTH: 2187

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 1

```

atgtgggtga ccaaactcct gccagccctg ctgetgcagc atgtcctcct gcatctctc 60
ctgctcccca tcgcatccc ctatgcagag ggacaaagga aaagaagaaa tacaattcat 120
gaattcaaaa aatcagcaaa gactacccta atcaaaatag atccagcact gaagataaaa 180
acaaaaaag tgaatactgc agaccaatgt gctaatagat gtactaggaa taaaggactt 240
ccattcactt gcaaggcttt tgtttttgat aaagcaagaa aacaatgcct ctggttcccc 300
ttcaatagca tgtcaagtgg agtgaaaaaa gaatttggcc atgaatttga cctctatgaa 360
aacaaagact acattagaaa ctgcatcatt ggtaaaggac gcagctacaa gggaacagta 420
tctatcacta agagtggcat caaatgtcag ccctggagtt ccatgatacc acacgaacac 480
agctttttgc cttcgagcta toggggtaaa gacctacagg aaaactactg tcgaaatcct 540
cgaggggaag aagggggacc ctggtgtttc acaagcaatc cagaggtacg ctacgaagtc 600
tgtgacattc ctcagtgttc agaagttgaa tgcatgacct gcaatgggga gagttatcga 660
ggtctcatgg atcatacaga atcaggcaag atttgtcagc gctgggatca tcagacacca 720
caccggcaca aattcttgcc tgaaagatat cccgacaagg gctttgatga taattattgc 780
cgcaatoccc atggccagcc gaggccatgg tgctatactc ttgaccctca caccgctgg 840
gagtactgtg caattaaaac atgcgctgac aatactatga atgacactga tgttcctttg 900
gaaacaactg aatgcatcca aggtcaagga gaaggctaca ggggcactgt caataccatt 960
tggaatggaa ttccatgtca gcgttgggat tctcagtatc ctcacgagca tgacatgact 1020

```

-continued

```

cctgaaaatt tcaagtcaa ggacctacga gaaaattact gccgaaatcc agatgggtct 1080
gaatcacccct ggtgttttac cactgatcca aacatccgag ttggctactg ctcccaaatt 1140
ccaaactgtg atatgtcaca tggacaagat tgttatcgtg ggaatggcaa aaattatatg 1200
ggcaacttat cccaaacaag atctggacta acatgttcaa tgtgggacaa gaacatggaa 1260
gacttacatc gtcatatctt ctgggaacca gatgcaagta agctgaatga gaattactgc 1320
cgaaatccag atgatgatgc tcatggaccc tgggtgctaca cgggaaatcc actcattcct 1380
tgggattatt gccctatttc tegtgtgaa ggtgatacca cacctacaat agtcaattta 1440
gaccatcccg taatatcttg tgccaaaacg aaacaattgc gagttgtaa tgggattcca 1500
acacgaacaa acataggatg gatggttagt ttgagataca gaaataaaca tatctgcgga 1560
ggatcattga taaaggagag ttgggttctt actgcacgac agtgtttccc ttctcgagac 1620
ttgaaagatt atgaagcttg gcttggaaatt catgatgtcc acggaagagg agatgagaaa 1680
tgcaaacagg ttctcaatgt ttcccagctg gtatatggcc ctgaaggatc agatctggtt 1740
ttaatgaagc ttgccaggcc tgctgtcctg gatgatcttg ttagtacgat tgatttacct 1800
aattatggat gcacaattcc tgaaaagacc agttgcagtg tttatggctg gggctacact 1860
ggattgatca actatgatgg cctattacga gtggcacatc tctatataat gggaaatgag 1920
aaatgcagcc agcatcatcg agggaaggtg actctgaatg agtctgaaat atgtgctggg 1980
gctgaaaaga ttggatcagg accatgtgag ggggattatg gtggcccact tgtttgtgag 2040
caacataaaa tgagaatggt tcttgggtgc attgttctcg gtcgtggatg tgccattcca 2100
aatcgtcctg gtatttttgt ccgagtagca tattatgcaa aatggataca caaaattatt 2160
ttaacatata aggtaccaca gtcatag 2187

```

<210> SEQ ID NO 2

<211> LENGTH: 7113

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 2

```

atgtgggtga ccaaactcct gccagccctg ctgctgcagc atgtcctcct gcctctctc 60
ctgctcccca tcgccatccc ctatgcagag ggacaaagga aaagaagaaa tacaattcat 120
gaattcaaaa aatcagcaaa gactacccta atcaaaatag atccagcact gaagataaaa 180
acaaaaaag tgaatactgc agaccaatgt gctaatagat gtactaggaa taaaggactt 240
ccattcactt gcaaggcttt tgtttttgat aaagcaagaa aacaatgcct ctggttcccc 300
ttcaatagca tgtcaagtgg agtgaaaaaa gaatttgccc atgaatttga cctctatgaa 360
aacaagact acattagaaa ctgcatcatt ggtaaaggac gcagctacaa gggaacagta 420
tctatcacta agagtggcat caaatgtcag ccctggagtt ccatgatacc acacgaacac 480
aggtaagaac agtatgaaga aaagagatga agcctctgtc tttttacat gttaacagtc 540
tcatattagt ccttcagaat aattctacaa tcctaaaata acttagccaa cttgctgaat 600
tgtattacgg caaggtttat atgaattcat gactgatatt tagcaaatga ttaattaata 660
tgtaataaaa atgtagccaa aacaatatct taccttaatg cctcaatttg tagatctcgg 720
tatttgtgaa ataataacgt aaacttcggt taaaaggatt cttcttctg tctttgagaa 780
agtacggcac tgtgcagggg gagaggttga ttgtgaaaaa tcagaggtag atgagaatct 840
tactgagggc tgagggttct ttaaccttgg tggatctcaa cattggttgc acattaaaat 900

```

-continued

cacctgctgc	aagcccttga	cgaatcttac	ttagaagatg	acaacacaga	acaattaaat	960
cagaatctct	ggggagaata	gggcaccagt	atTTTTtgag	ctcccaccat	gattccaaag	1020
tgacgcaaaa	tttgagaacc	actgctaaaa	gctcaagctt	cagattgacc	agcttttcca	1080
tctcacctat	cgcctaaaga	ccaaattgga	taaatgtggt	cattacgaca	gatgggtact	1140
atTTaaagat	gagtaaacac	aatatactta	ggctcgtcag	actgagagtt	ttaatcatca	1200
ctgaggaaaa	acatagatat	ctaatactga	ctggagtatt	agtcaaggct	tatttcacac	1260
acaatTTtat	cagaaaccaa	agtagtttaa	aacagctctc	cccttattag	taatgcattg	1320
gagggtttac	tttaccatgt	accttgctga	gcactgtacc	ttgttaatct	catttacttg	1380
taatgagaac	cacacagcgg	gtagttttat	tggttctatt	ttacctacat	gacaaaactg	1440
aagcataaaa	acacttagta	agTTTTcagt	gtcatgcaca	actaggaagt	gacatggcca	1500
gaatataagc	ccagtcacca	tactctata	acctgcgctt	ttaacaactt	cagggcatga	1560
cacatttggc	cggtcagtag	aacctatgct	gtgatttgtt	tttgcagtgg	tggtgatgac	1620
tgcttgttg	aatccacttt	ttattctatt	ccattttggg	gacacaattc	tgcaagatga	1680
ttcttcatta	ggaaacagag	atgagttatt	gaccaacaca	gaaagaaaaa	gagtttgttg	1740
ctccacactg	ggattaaacc	tatgatcttg	gcctaattaa	cactagctag	taagtgtcca	1800
agctgatcat	ctctacaaca	tttcaataac	agaaaaaac	aatTTTcaaa	attagttact	1860
tacaattatg	tagaaatgcc	tctaaaacac	agtattttcc	ttatattaca	aaaacaaaaa	1920
ttataattgg	ttttgtctc	ttttgagagt	ttgcatggtg	ttactcctg	catagtgaag	1980
aaaacatttt	atTTaagtag	atggatctaa	gtTTTTcatg	aacaaaggaa	tgacatttga	2040
aatcaatcct	accctagtcc	aggagaatgc	attagattaa	cctagtagag	gtcttatttc	2100
accctgagtt	ttctatgatc	gtgattctct	gctggaggag	taattgtgaa	atagatctct	2160
ctgggaactg	gcttctagt	ccaatcagct	cttttaccaa	tgaacacttc	cttgtgatat	2220
agatgtttat	ggccgagagg	atccagtata	ttaataaaat	ccctttttgt	attcaatgag	2280
ggaaacacat	aatTTTcatc	aattagcagc	ttattggaat	atctgcatga	tggtttaaca	2340
ctTTtaagtg	ttgactaaag	attaatttta	cagaaaatag	aaaaagaaat	atgtttctgt	2400
ctggaggaat	gatttattgt	tgacccttaa	attgaaatat	tttactagtg	gcttaatgga	2460
aagatgatga	aagatgatga	aattaatgta	gaagcttaac	tagaaaatca	ggtgacctga	2520
tatctacatc	tgtatccttc	attggccacc	cagcattcat	taatgaatca	gatgatggaa	2580
tagatcaagt	ttcctaggaa	cacagtgaat	attaaaagaa	aacaaaggga	gcctagcacc	2640
tagaagacct	agtttatatt	tcaaagtata	tttggatgta	acccaatttt	aaacatttcc	2700
tacttgtct	ctcttaaagc	cttgccaaca	gcaaggacag	agaacaaaaa	atagtgtata	2760
tatgaataaa	tgcttattac	agaatctgct	gactggcaca	tgctttgtgt	gtaatgggtt	2820
ctcataaaca	cttgttgaat	gaacacacat	aagtgaaaga	gcatggctag	gcttcatccc	2880
ttggTcaaat	atggggTgct	aaagaaaagc	aggggaaata	cattggggaca	ctaacaaaaa	2940
aaaacagtta	atTTtaggtaa	aagataaaat	acaccacaga	atgaagaaaa	gagatgaccc	3000
agactgctct	ttaaccttca	tgtcctagag	aggtTTTTga	tatgaattgc	attcagaatt	3060
gtggaaagga	gcccactttt	tctcttcatt	ttgattttat	taactccaat	gggggaattt	3120
tattcgtggt	ttggccatat	ctacttttga	tttctacatt	attctctctt	cctttctacc	3180
tgtatttgtc	ctaataaatt	gttgacttat	taattcacta	cttctcaca	gctttttttt	3240
ggctttacaa	atccactgga	aaggTatatg	ggtgtatcac	tttgtgtatt	tcggTgtgca	3300

-continued

tgtgtagagg	ggacaaaaat	cctctctcaa	actataaata	ttgagtattt	gtgtattgaa	3360
catttgctat	aactactagg	tttcttaaat	aatcttaata	tataaaatga	tatagaaaaa	3420
gggaaattat	agttcgtatt	attcatctaa	gtgaagagat	taaaaccag	ggagtaaata	3480
aattgtctaa	ggactaaggt	tgtatactat	ttaggtgata	gatatggggc	aaccgtatgg	3540
gttttatgat	taacaaataa	acttctcacc	actctaccat	atcaactttt	ccataaaaaga	3600
gagctatagt	attctttgct	taaataaatt	tgattagtgc	atgacttctt	gaaaacatat	3660
aaagcaaaag	tcacatttga	ttctatcaga	aaagtgagta	agccatggcc	caaacaaaag	3720
atgcattaaa	atattctgga	atgatggagc	taaaagtaag	aaaaatgact	ttttaaaaaa	3780
gtttactggt	aggaattgtg	aaattatgct	gaattttagt	tgcattataa	tttttgtcag	3840
tcatacggtc	tgacaacctg	tcttatttct	atttccccat	atgaggaatg	ctagttaagt	3900
atggatatta	actattacta	cttagatgca	ttgaagttgc	ataatatgga	taatacttca	3960
ctggttccct	gaaaatgttt	agttagtaat	aagtctctta	cactatttgt	tttgtccaat	4020
aatttatatt	ttctgaagac	ttaactctag	aatacactca	tgtcaaaatg	aaagaatttc	4080
attgcaaaat	attgcttggc	acatgacgca	tacctgtatt	tgttttgtgt	cacaacatga	4140
aaaatgatgg	tttattagaa	gtttcattgg	gtaggaaaca	catttgaatg	gtatttacta	4200
agatactaaa	atccttggac	ttcactctaa	ttttagtgcc	attagaact	caaggtctca	4260
gtaaaagtag	aaataaagcc	tgtaacaaa	acacaagctg	aatattaaaa	atgtaactgg	4320
attttcaaag	aatgtttac	tggtattacc	tgtagatgta	tattctttat	tatgatcttt	4380
tgtgtaaagt	ctggcagaca	aatgcaatat	ctaattgttg	agtccaatat	cacaagcagt	4440
acaaaagtat	aaaaaagact	tggccttttc	taatgtgta	aaatacttta	tgctggtaat	4500
aacactaaga	gtagggcact	agaaatttta	agtgaagata	atgtggtgca	gttactgcac	4560
tcaatggctt	actattataa	acaaaaactg	ggatcactaa	gctccagtca	gtcaaaatga	4620
tcaaaattat	tgaagagaat	aagcaattct	gttctttatt	aggacacagt	agatacagac	4680
tacaaagtgg	agtgtgctta	ataagaggta	gcatttgta	agtgtcaatt	actctattat	4740
cccttgagc	ttctcaaaat	aacctataa	ggtgtaagat	gttaaagggt	atggttacac	4800
tcagtgcaca	ggtaagctaa	taggctgaga	gaagctaaat	tacttactgg	ggtctcacag	4860
taagaaagtg	agctgaagtt	tcagcccaga	tttaactgga	ttctgggctc	tttattcatg	4920
ttacttcatg	aatctgtttc	tcaattgtgc	agaaaaaagg	gggctattta	taagaaaagc	4980
aataaacaaa	caagtaatga	tctcaaataa	gtaatgcaag	aaatagtgag	atttcaaaat	5040
cagtggcagc	gatttctcag	ttctgtccta	agtggccttg	ctcaatcacc	tgctatcttt	5100
tagtggagct	ttgaaattat	gtttcagaca	acttcgattc	agttctagaa	tgtttgactc	5160
agcaaattca	caggctcatc	tttctaactt	gatggtgaat	atggaaattc	agctaaatgg	5220
atgttaataa	aattcaaacg	ttttaaggac	agatgaaaat	gacagaattt	taaggtaaaa	5280
tatatgaagg	aatataagat	aaaggatttt	tctaccttca	gcaaaaacat	accactaat	5340
tagtaaaatt	aataggcaaa	aaaaagttgc	atgctcttat	actgtaatga	ttatcatttt	5400
aaaactagct	ttttgccttc	gagctatcgg	ggtaaagacc	tacaggaaaa	ctactgtcga	5460
aatcctogag	gggaagaagg	gggaccctgg	tgtttcacia	gcaatccaga	ggtacgctac	5520
gaagtctgtg	acattcctca	gtgttcagaa	gttgaatgca	tgacctgcaa	tggggagagt	5580
tatcgaggtc	tcatggatca	tacagaatca	ggcaagattt	gtcagcgctg	ggatcatcag	5640

-continued

```

acaccacacc ggcacaaatt cttgcctgaa agatatcccg acaagggtt tgatgataat 5700
tattgccgca atcccgatgg ccagccgagg ccatggtgct atactcttga ccctcacacc 5760
cgctgggagt actgtgcaat taaaacatgc gctgacaata ctatgaatga cactgatggt 5820
cctttggaaa caactgaatg catccaaggt caaggagaag gctacagggg cactgtcaat 5880
accatttggga atggaattcc atgtcagcgt tgggattctc agtatcctca cgagcatgac 5940
atgactcctg aaaatttcaa gtgcaaggac ctacgagaaa attactgccg aaatccagat 6000
gggtctgaat caccctggtg ttttaccact gatccaaaca tccgagttgg ctactgctcc 6060
caaattccaa actgtgatat gtcacatgga caagattggt atcgtgggaa tggcaaaaat 6120
tatatgggca acttatcca aacaagatct ggactaacat gttcaatgtg ggacaagaac 6180
atggaagact tacatcgtca tatcttctgg gaaccagatg caagtaagct gaatgagaat 6240
tactgccgaa atccagatga tgatgctcat ggaccctggt gctacacggg aaatccactc 6300
attccttggg attattgccc ttttctcgt tgtgaagggtg ataccacacc tacaatagtc 6360
aatttagacc atcccgtaat atcttgtgcc aaaacgaaac aattgagagt tgtaaatggg 6420
attccaacac gaacaaacat aggatggatg gttagtttga gatacagaaa taaacatatc 6480
tgcggaggat cattgataaa ggagagttgg gttcttactg cacgacagtg tttcccttct 6540
cgagacttga aagattatga agcttggctt ggaattcatg atgtccacgg aagaggagat 6600
gagaaatgca aacaggttct caatgtttcc cagctggtat atggccctga aggatcagat 6660
ctggttttaa tgaagcttgc caggcctgct gtcttggatg attttgttag tacgattgat 6720
ttacctaatt atggatgcac aattcctgaa aagaccagtt gcagtgttta tggctggggc 6780
tacactggat tgatcaacta tgatggccta ttacgagtgg cacatctcta tataatggga 6840
aatgagaaat gcagccagca tcatcgaggg aaggtgactc tgaatgagtc tgaaatatgt 6900
gctggggctg aaaagattgg atcaggacca tgtgaggggg attatggtgg cccacttggt 6960
tgtgagcaac ataaaatgag aatggttctt ggtgtcattg ttcttggctg tggatgtgcc 7020
attccaaatc gtcttggat ttttgtccga gtagcatatt atgcaaaatg gatacacaaa 7080
attattttaa catataaggt accacagtca tag 7113

```

```

<210> SEQ ID NO 3
<211> LENGTH: 34
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: gHGF3 primer

```

```

<400> SEQUENCE: 3

```

```

gtaaaggacg cgtctacaag ggaacagtat ctat 34

```

```

<210> SEQ ID NO 4
<211> LENGTH: 27
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: gHGF4 primer

```

```

<400> SEQUENCE: 4

```

```

actggatcct ctcggccata aacatct 27

```

```

<210> SEQ ID NO 5
<211> LENGTH: 34
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence

```

-continued

<220> FEATURE:
<223> OTHER INFORMATION: gHGF10 primer

<400> SEQUENCE: 5

gaagcttagc accatgtggg tgaccaaact cctg 34

<210> SEQ ID NO 6
<211> LENGTH: 27
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: gHGF5 primer

<400> SEQUENCE: 6

tggccgagag gatccagtat attaata 27

<210> SEQ ID NO 7
<211> LENGTH: 27
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: gHGF7 primer

<400> SEQUENCE: 7

cccctcgagg atttcgacag tagtttt 27

<210> SEQ ID NO 8
<211> LENGTH: 28
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: gHGF12 primer

<400> SEQUENCE: 8

gggatccctt cctttctacc tgtatttg 28

<210> SEQ ID NO 9
<211> LENGTH: 25
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: gHGF13 primer

<400> SEQUENCE: 9

gggatcctgg gtaaacacat ttgaa 25

<210> SEQ ID NO 10
<211> LENGTH: 28
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: gHGF6 primer

<400> SEQUENCE: 10

gggatcctta tgtttcagac aacttcga 28

<210> SEQ ID NO 11
<211> LENGTH: 34
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: gHGF1 primer

<400> SEQUENCE: 11

gaagcttgcc accatgtggg tgaccaaact cctg 34

-continued

<210> SEQ ID NO 12
<211> LENGTH: 34
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: gHGF2 primer

<400> SEQUENCE: 12

gggatccaga acgcgtcctt taccgatgat gcag 34

<210> SEQ ID NO 13
<211> LENGTH: 35
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: gHGF8 primer

<400> SEQUENCE: 13

gggatccctt ctcgagactt gaaagattat gaagc 35

<210> SEQ ID NO 14
<211> LENGTH: 32
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: gHGF9 primer

<400> SEQUENCE: 14

gtctagagcg gccgctatga ctgtggtacc tt 32

<210> SEQ ID NO 15
<211> LENGTH: 36
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: cHGF5 primer

<400> SEQUENCE: 15

ggatccacgc gtagcagcac catgtgggtg accaaa 36

<210> SEQ ID NO 16
<211> LENGTH: 36
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: cHGF3 primer

<400> SEQUENCE: 16

ggatcctcta gattacttca gctatgactg tggtac 36

<210> SEQ ID NO 17
<211> LENGTH: 26
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: GHGF5' primer

<400> SEQUENCE: 17

caaatgtagc ccctggagtt ccatga 26

<210> SEQ ID NO 18
<211> LENGTH: 23
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: GHGF3' primer

-continued

<400> SEQUENCE: 18

ctggattgct tgtgaaacag ggt	23
---------------------------	----

<210> SEQ ID NO 19

<211> LENGTH: 4679

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: HGF-X6 gene

<400> SEQUENCE: 19

atgtgggtga ccaaactcct gccagccctg ctgctgcagc atgtcctcct gcatctcctc	60
ctgctcccca tcgccatccc ctatgcagag ggacaaagga aaagaagaaa tacaattcat	120
gaattcaaaa aatcagcaaa gactacccta atcaaatag atccagcact gaagataaaa	180
acaaaaaag tgaatactgc agaccaatgt gctaatagat gtactaggaa taaaggactt	240
ccattcactt gcaaggcttt tgtttttgat aaagcaagaa aacaatgcct ctggttcccc	300
ttcaatagca tgtcaagtgg agtgaaaaaa gaatttggcc atgaatttga cctctatgaa	360
aacaaagact acattagaaa ctgcatcatc ggtaaaggac gcagctaaa gggaacagta	420
tctatcacta agagtggcat caaatgtcag ccttgagatt ccatgatacc acacgaacac	480
aggtaagaac agtatgaaga aaagagatga agcctctgtc ttttttacct gttaacagtc	540
tcatattagt ccttcagaat aattctacaa tctaaaata acttagccaa cttgctgaat	600
tgtattacgg caaggtttat atgaattcat gactgatatt tagcaaatga ttaattaata	660
tgtaataaaa atgtagccaa aacaatatct taccttaatg cctcaatttg tagatctcgg	720
tatttgtgga tcccttcctt tctacctgta tttgtcctaa taaattgttg acttattaat	780
tcactacttc ctcacagctt ttttttggct ttacaaatcc actggaaagg tatatgggtg	840
tatcactttg tgtatttcgg tgtgcatgtg tagaggggac aaaaatcctc tctcaacta	900
taaataattg gtatttgtgt attgaacatt tgctataact actaggtttc ttaaataatc	960
ttaatatata aatgatata gaaaaaggga aattatagtt cgtattattc atctaagtga	1020
agagattaaa acccaggag taaataaatt gtctaaggac taaggttgta tactatttag	1080
gtgatagata tggggcaacc gtatgggttt tatgattaac aaataaactt ctcaccactc	1140
taccatatca acttttccat aaaagagagc tatagtattc tttgcttaa taaatttgat	1200
tagtgcata cttcttgaac acatataaag caaaagtcac atttgattct atcagaaaag	1260
tgagtaagcc atggcccaaa caaaagatgc attaaaatat tctggaatga tggagctaaa	1320
agtaagaaaa atgacttttt aaaaaagttt actgttagga attgtgaaat tatgctgaat	1380
tttagttgca ttataatttt tgtcagtcac acggtctgac aacctgtctt atttctattt	1440
ccccatatga ggaatgctag ttaagtatgg atattaacta ttactactta gatgcattga	1500
agttgcataa tatggataat acttcactgg ttccctgaaa atgttttagt agtaataagt	1560
ctcttacct atttgttttg tccaataatt tatattttct gaagacttaa ctctagaata	1620
cactcatgtc aaaatgaaag aatttcattg caaaatattg cttggtacat gacgcatacc	1680
tgtatttggt ttgtgtcaca acatgaaaaa tgatggttta ttagaagttt cattgggtag	1740
gaaacacatt tgaatggtat ttactaagat actaaaatcc ttggacttca ctctaatttt	1800
agtgccattt agaactcaag gtctcagtaa aagtagaaat aaagcctgtt aacaaaacac	1860
aagctgaata ttaaaaatgt aactggattt tcaaagaaat gtttactggt attacctgta	1920

-continued

gatgtatatt	ctttattatg	atcttttgtg	taaagtctgg	cagacaaatg	caatatctaa	1980
ttgttgagtc	caatatacaca	agcagtacaa	aagtataaaa	aagacttggc	cttttctaata	2040
gtgttaaaat	actttatgct	ggtaataaca	ctaagagtag	ggcactagaa	attttaagtg	2100
aagataatgt	gttgcagtta	ctgcactcaa	tggcttacta	ttataaacca	aaactgggat	2160
cactaagctc	cagtcagtca	aaatgatcaa	aattattgaa	gagaataagc	aattctgttc	2220
ttatttagga	cacagtagat	acagactaca	aagtggagtg	tgcttaataa	gaggtagcat	2280
ttgttaagtg	tcaattactc	tattatccct	tggagcttct	caaaataacc	atataagggtg	2340
taagatgtta	aaggttatgg	ttacactcag	tgcacaggta	agctaatagg	ctgagagaag	2400
ctaaattact	tactggggtc	tcacagtaag	aaagtgagct	gaagtttcag	cccagattta	2460
actggattct	gggctcttta	ttcatgttac	ttcatgaatc	tgtttctcaa	ttgtgcagaa	2520
aaaagggggc	tatttataag	aaaagcaata	aacaaacaag	taatgatctc	aaataagtaa	2580
tgcaagaaat	agtgagattt	caaaatcagt	ggcagcgatt	tctcagttct	gtcctaagtg	2640
gccttgctca	atcacctgct	atcttttagt	ggagctttga	aattatgttt	cagacaactt	2700
cgattcagtt	ctagaatggt	tgactcagca	aattcacagg	ctcatcttcc	taacttgatg	2760
gtgaatatgg	aaattcagct	aatggatgt	taataaaatt	caaacgtttt	aaggacagat	2820
gaaaatgaca	gaattttaag	gtaaaatata	tgaaggaata	taagataaag	gatttttcta	2880
ccttcagcaa	aaacataccc	actaattagt	aaaattaata	ggcaaaaaaa	agttgcatgc	2940
tcttatactg	taatgattat	cattttaaaa	ctagcttttt	gccttcgagc	tatcggggta	3000
aagacctaca	ggaaaactac	tgtcgaaatc	ctcgagggga	agaaggggga	ccctgggtgtt	3060
tcacaagcaa	tccagaggta	cgctacgaag	tctgtgacat	tcctcagtgt	tcagaagttg	3120
aatgcatgac	ctgcaatggg	gagagttatc	gaggtctcat	ggatcataca	gaatcaggca	3180
agatttgca	gcgctgggat	catcagacac	cacaccggca	caaattcttg	cctgaaagat	3240
atcccagcaa	gggctttgat	gataattatt	gccgcaatcc	cgatggccag	ccgaggccat	3300
ggtgctatac	tcttgaccct	cacacccgct	gggagtactg	tgcaattaaa	acatgcgctg	3360
acaatactat	gaatgacact	gatgttcctt	tggaaacaac	tgaatgcatc	caaggtcaag	3420
gagaaggcta	caggggcact	gtcaatacca	tttggaatgg	aattccatgt	cagcgttggg	3480
attctcagta	tcctcacgag	catgacatga	ctcctgaaaa	tttcaagtgc	aaggacctac	3540
gagaaaatta	ctgccgaaat	ccagatgggt	ctgaatcacc	ctgggtgttt	accactgatc	3600
caaacatccg	agttggctac	tgctcccaaa	ttccaaactg	tgatatgtca	catggacaag	3660
attgttatcg	tgggaatggc	aaaaattata	tgggcaactt	atcccaaaca	agatctggac	3720
taacatgttc	aatgtgggac	aagaacatgg	aagacttaca	tcgtcatatc	ttctgggaac	3780
cagatgcaag	taagctgaat	gagaattact	gccgaaatcc	agatgatgat	gctcatggac	3840
cctggtgcta	cacgggaaat	ccactcattc	cttgggatta	ttgcctatt	tctcgttgtg	3900
aaggtgatac	cacacctaca	atagtcaatt	tagaccatcc	cgtaatatct	tgtgccaaaa	3960
cgaaacaatt	gaggttgta	aatgggattc	caacacgaac	aaacatagga	tggatggtta	4020
gtttgagata	cagaaataaa	catatctgcg	gaggatcatt	gataaaggag	agttgggttc	4080
ttactgcacg	acagtgttcc	ccttctcgag	acttgaaaga	ttatgaagct	tggcttgaa	4140
ttcatgatgt	ccacggaaga	ggagatgaga	aatgcaaaca	ggttctcaat	gtttcccagc	4200
tggtatatgg	ccctgaagga	tcagatctgg	ttttaatgaa	gcttgccagg	cctgctgtcc	4260
tggatgattt	tgtagtacg	attgatttac	ctaattatgg	atgcacaatt	cctgaaaaga	4320

-continued

```

ccagttgcag tgtttatggc tggggctaca ctggattgat caactatgat ggcctattac 4380
gagtggcaca tctctatata atgggaaatg agaaatgcag ccagcatcat cgaggggaagg 4440
tgactctgaa tgagtctgaa atatgtgctg gggctgaaaa gattggatca ggaccatgtg 4500
agggggatta tgggtggcca cttgtttgtg agcaacataa aatgagaatg gttcttgggtg 4560
tcattgttcc tggtcgtgga tgtgccattc caaatcgtcc tggatatttt gtccgagtag 4620
catattatgc aaaatggata cacaaaatta ttttaacata taaggtacca cagtcatag 4679

```

```

<210> SEQ ID NO 20
<211> LENGTH: 3679
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: HGF-X7 gene

```

```

<400> SEQUENCE: 20

```

```

atgtgggtga ccaaactcct gccagccctg ctgctgcagc atgtcctcct gcatctcctc 60
ctgctcccca tcgccatccc ctatgcagag ggacaaagga aaagaagaaa tacaattcat 120
gaattcaaaa aatcagcaaa gactacccta atcaaaatag atccagcact gaagataaaa 180
accaaaaaag tgaatactgc agaccaatgt gctaatagat gtactaggaa taaaggactt 240
ccattcactt gcaaggcttt tgtttttgat aaagcaagaa aacaatgcct ctggttcccc 300
ttcaatagca tgtcaagtgg agtgaaaaaa gaatttggcc atgaatttga cctctatgaa 360
aacaagact acattagaaa ctgcatcadc ggtaaaggac gcagctacaa gggaacagta 420
tctatcacta agagtggcat caaatgtcag cctggagtt ccatgatacc acacgaacac 480
aggtaagaac agtatgaaga aaagagatga agcctctgtc ttttttacct gttaacagtc 540
tcatattagt ccttcagaat aattctacaa tctaaaata acttagcaa cttgctgaat 600
tgtattacgg caaggtttat atgaattcat gactgatatt tagcaaatga ttaattaata 660
tgtaataaaa atgtagcaa aacaatatct taccttaatg cctcaatttg tagatctcgg 720
tatttgtgga tcctgggtag gaaacacatt tgaatggat ttactaagat actaaaatcc 780
ttggacttca ctctaatttt agtgccattt agaactcaag gtctcagtaa aagtagaaat 840
aaagcctggt acaaaaacac aagctgaata ttaaaaatgt aactggattt tcaaagaaat 900
gtttactggg attacctgta gatgtatatt ctttattatg atcttttgtg taaagtctgg 960
cagacaaatg caatatctaa ttgttgagtc caatatcaca agcagtacaa aagtataaaa 1020
aagacttggc cttttctaag gtgttaaaat actttatgct ggtaataaca ctaagagtag 1080
ggcactagaa attttaagtg aagataatgt gttgcagtta ctgcactcaa tggcttacta 1140
ttataaacca aaactgggat cactaagctc cagtccagtc aaatgatcaa aattattgaa 1200
gagaataagc aattctgttc tttattagga cacagtagat acagactaca aagtggagtg 1260
tgcttaataa gaggtagcat ttgttaagtg tcaattactc tattatccct tggagcttct 1320
caaaaataacc atataaggtg taagatgtta aaggttatgg ttacactcag tgcacaggta 1380
agctaatagg ctgagagaag ctaaattact tactggggtc tcacagtaag aaagtgagct 1440
gaagtttcag cccagattta actggattct gggctcttta ttcattgtac ttcattgaatc 1500
tgtttctcaa ttgtgcagaa aaaagggggc tatttataag aaaagcaata acaaaacaag 1560
taatgatctc aaataagtaa tgcaagaaat agtgagattt caaatcagt ggcagcgatt 1620
tctcagttct gtccaaagtg gccttgctca atcacctgct atcttttagt ggagctttga 1680

```

-continued

```

aattatgttt cagacaactt cgattcagtt ctagaatggt tgactcagca aattcacagg 1740
ctcatctttc taacttgatg gtgaatatgg aaattcagct aaatggatgt taataaaatt 1800
caaacgtttt aaggacagat gaaaatgaca gaattttaag gtaaaatata tgaaggaata 1860
taagataaag gatttttcta ccttcagcaa aaacataccc actaattagt aaaattaata 1920
ggcaaaaaaa agttgcatgc tttatactg taatgattat cattttaaaa ctagcttttt 1980
gccttcgagc tatcggggta aagacctaca ggaaaactac tgtcgaaatc ctogagggga 2040
agaaggggga ccttggtggt tcacaagcaa tccagaggta cgctacgaag tctgtgacat 2100
tcctcagtggt tcagaagttg aatgcatgac ctgcaatggg gagagttatc gaggtctcat 2160
ggatcataca gaatcaggca agatttgta gcgctgggat catcagacac cacaccggca 2220
caaattcttg cctgaaagat atcccagaca gggctttgat gataattatt gccgcaatcc 2280
cgatggccag ccgaggccat ggtgctatac tcttgaccct cacaccgct gggagtactg 2340
tgcaattaa acatgcgctg acaatactat gaatgacact gatgttcctt tggaaacaac 2400
tgaatgcatc caaggtcaag gagaaggcta caggggact gtcaatacca tttggaatgg 2460
aattccatgt cagcgttggg attctcagta tcctcacgag catgacatga ctctgaaaa 2520
tttcaagtgc aaggacctac gagaaaatta ctgccgaaat ccagatgggt ctgaatcacc 2580
ctgggtgttt accactgatc caaacatccg agttggctac tgctcccaa ttccaaactg 2640
tgatatgtca catggacaag attggtatcg tgggaatggc aaaaattata tgggcaactt 2700
atcccaaaca agatctggac taacatgttc aatgtgggac aagaacatgg aagacttaca 2760
tcgtcatatc ttctgggaac cagatgcaag taagctgaat gagaattact gccgaaatcc 2820
agatgatgat gctcatggac cctggtgcta cacgggaaat ccactcattc cttgggatta 2880
ttgccctatt tctcgttggt aaggtgatac cacacctaca atagtcaatt tagaccatcc 2940
cgtaatatct tgtgccaaaa cgaaacaatt gcgagttgta aatgggattc caacacgaac 3000
aaacatagga tggatggtta gtttgagata cagaaataaa catatctgag gaggatcatt 3060
gataaaggag agttgggttc ttactgcacg acagtgtttc ccttctcgag acttgaaaga 3120
ttatgaagct tggcttggaa ttcgatgatg ccacggaaga ggagatgaga aatgcaaaca 3180
ggttctcaat gtttccagc tggatatgg cctgaagga tcagatctgg ttttaatgaa 3240
gcttgccagg cctgctgtcc tggatgattt tgtagtacg attgatttac ctaattatgg 3300
atgcacaatt cctgaaaaga ccagttgcag tgtttatggc tggggctaca ctggattgat 3360
caactatgat ggcctattac gagtggcaca tctctatata atgggaaatg agaaatgcag 3420
ccagcatcat cgaggaagg tgactctgaa tgagtctgaa atatgtgctg gggctgaaaa 3480
gattggatca ggaccatgtg agggggatta tggtgccca cttgttgtg agcaacataa 3540
aatgagaatg gttcttgggt tcattgttcc tggctgtgga tgtgccattc caaatcgtcc 3600
tggatTTTTT gtccgagtag catattatgc aaaatggata cacaaaatta ttttaacata 3660
taaggtacca cagtcatag 3679

```

```

<210> SEQ ID NO 21
<211> LENGTH: 2729
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: HGF-X8 gene

```

```

<400> SEQUENCE: 21

```

```

atgtgggtga ccaaactcct gccagccctg ctgctgcagc atgtcctcct gcctctctc 60

```

-continued

ctgctcccca	tcgcatccc	ctatgcagag	ggacaaagga	aaagaagaaa	tacaattcat	120
gaattcaaaa	aatcagcaaa	gactacccta	atcaaaatag	atccagcact	gaagataaaa	180
acaaaaaag	tgaatactgc	agaccaatgt	gctaatagat	gtactaggaa	taaaggactt	240
ccattcactt	gcaaggcttt	tgtttttgat	aaagcaagaa	aacaatgcct	ctggttcccc	300
ttcaatagca	tgtcaagtgg	agtgaaaaaa	gaatttggcc	atgaatttga	cctctatgaa	360
aacaaagact	acattagaaa	ctgcatcatc	ggtaaaggac	gcagctacaa	gggaacagta	420
tctatcacta	agagtggcat	caaatgtcag	ccctggagtt	ccatgatacc	acacgaacac	480
aggtaagaac	agtatgaaga	aaagagatga	agcctctgtc	ttttttacat	gttaacagtc	540
tcatattagt	ccttcagaat	aattctacaa	tcctaaaata	acttagccaa	cttgctgaat	600
tgtattacgg	caaggtttat	atgaattcat	gactgatatt	tagcaaatga	ttaattaata	660
tgtaataaaa	atgtagccaa	aacaatatct	taccttaatg	cctcaatttg	tagatctcgg	720
tatttgagg	tccttatgtt	tcagacaact	tcgattcagt	tctagaatgt	ttgactcagc	780
aaattcacag	gctcatcttt	ctaacttgat	ggatgaatag	gaaattcagc	taaattggatg	840
ttaataaaat	tcaaactgtt	taaggacaga	tgaaaatgac	agaattttaa	ggtaaaatat	900
atgaaggaat	ataagataaa	ggatttttct	accttcagca	aaaacatacc	cactaattag	960
taaaattaat	aggcaaaaaa	aagttgcatg	ctcttatact	gtaatgatta	tcattttaaa	1020
actagctttt	tgccttcgag	ctatcggggg	aaagacctac	aggaaaacta	ctgtcgaaat	1080
cctcgagggg	aagaaggggg	accctgggtg	ttcacaagca	atccagaggt	acgctacgaa	1140
gtctgtgaca	ttcctcagtg	ttcagaagtt	gaatgcatga	cctgcaatgg	ggagagttat	1200
cgaggctca	tggatcatac	agaatcaggc	aagatttgtc	agcgctggga	tcacagaca	1260
ccacacoggc	acaaattctt	gcctgaaaga	tatcccagca	agggctttga	tgataattat	1320
tgccgcaatc	ccgatggcca	gccgaggcca	tggtgctata	ctcttgacct	tcacacccgc	1380
tgggagtact	gtgcaattaa	aacatgcgct	gacaatacta	tgaatgacac	tgatgttcct	1440
ttgaaacaa	ctgaatgcat	ccaaggtcaa	ggagaaggct	acagggggac	tgtcaatacc	1500
atttggaatg	gaattccatg	tcagcgttgg	gattctcagt	atcctcacga	gcatgacatg	1560
actcctgaaa	atttcaagtg	caaggaccta	cgagaaaatt	actgccgaaa	tccagatggg	1620
ctgaatcacc	ctggtgtttt	accactgatc	caaacatccg	agttggctac	tgctcccaaa	1680
ttccaaactg	tgatatgtca	catggacaag	attgttatcg	tgggaatggc	aaaaattata	1740
tgggcaactt	atcccaacaa	agatctggac	taacatgttc	aatgtgggac	aagaacatgg	1800
aagacttaca	tcgtcatatc	ttctgggaac	cagatgcaag	taagctgaat	gagaattact	1860
gccgaaatcc	agatgatgat	gctcatggac	cctgggtgcta	cacgggaaat	ccactcattc	1920
cttgggatta	ttgccctatt	tctcgttgtg	aaggtgatac	cacacctaca	atagtcaatt	1980
tagaccatcc	cgtaatatct	tgtgccaaaa	cgaaacaatt	gcgagttgta	aatgggatcc	2040
caacacgaac	aaacatagga	tggatggtta	gtttgagata	cagaaataaa	catatctgcg	2100
gaggatcatt	gataaaggag	agttgggttc	ttactgcacg	acagtgtttc	ccttctcgag	2160
acttgaagaa	ttatgaagct	tggcttgga	ttcatgatgt	ccacggaaga	ggagatgaga	2220
aatgcaaaaca	ggttctcaat	gtttcccagc	tggtatatgg	ccctgaagga	tcagatctgg	2280
ttttaatgaa	gcttgccagg	cctgctgtcc	tggatgatth	tgtagtacg	attgatttac	2340
ctaattatgg	atgcacaatt	cctgaaaaga	ccagttgcag	tgtttatggc	tggggctaca	2400

-continued

ctggattgat caactatgat ggcttattac gactggcaca tctctatata atgggaaatg	2460
agaaatgcag ccagcatcat cgaggggaagg tgactctgaa tgagtctgaa atatgtgctg	2520
gggctgaaaa gattggatca ggaccatgtg agggggatta tgggtggccca cttgtttgtg	2580
agcaacataa aatgagaatg gttcttggtg tcattgttcc tggctcgtga tgtgccattc	2640
caaatcgtcc tggatatttt gtccgagtag catattatgc aaaatggata cacaaaatta	2700
ttttaacata taaggtacca cagtcatag	2729

What is claimed is:

1. A method for co-expressing two heterotypes of Hepatocyte Growth Factor (HGF) *in vivo in a mammalian subject with ischemic disease in order to treat the disease*, comprising:

transforming or transfecting [to] a DNA construct into a cell of a mammalian subject with ischemic disease by administering a DNA construct to the subject, the DNA construct comprising:

- (a) a promoter,
- (b) a first cDNA which has the same sequence as exons 1-4 of the human HGF gene wherein said exons 1-4 are arranged in sequential order without an intron therebetween, or degenerates thereof which do not alter the amino acid sequence encoded by said first cDNA,
- (c) a polynucleotide that has the same sequence as intron 4 of the HGF gene or a functional fragment thereof, and
- (d) a second cDNA which has the same sequence as exons 5-18 of the human HGF gene wherein said exons 5-18 are arranged in sequential order without an intron therebetween, or degenerates thereof which do not alter the amino acid sequence encoded by said second cDNA;

wherein (c) is located between (b) and (d); and the HGF construct simultaneously encodes two heterotypes of human HGF, and

whereby two heterotypes of human HGF are co-expressed within the mammalian subject, thereby treating the ischemic disease.

2. The method of claim 1, wherein said intron has the same sequence as a fragment of intron 4 of the HGF gene.

3. The method of claim 2, wherein the construct comprises a nucleotide sequence not less than 90% identical to SEQ ID NO: 19.

4. The method of claim 3, wherein the construct comprises a nucleotide sequence not less than 95% identical to SEQ ID NO: 19.

5. The method of claim 4, wherein the construct comprises the sequence of SEQ ID NO: 19.

6. The method of claim 2, wherein the construct comprises a nucleotide sequence not less than 90% identical to SEQ ID NO: 20.

7. The method of claim 6, wherein the construct comprises a nucleotide sequence not less than 95% identical to SEQ ID NO: 20.

8. The method of claim 7, wherein the construct comprises the sequence of SEQ ID NO: 20.

9. The method of claim 2, wherein the construct comprises a nucleotide sequence not less than 90% identical to SEQ ID NO: 21.

10. The method of claim 9, wherein the construct comprises a nucleotide sequence not less than 95% identical to SEQ ID NO: 21.

11. The method of claim 10, wherein the construct comprises the sequence of SEQ ID NO: 21.

12. The method of claim 1, wherein the one intron has the same sequence as the full intron 4 of the HGF gene.

13. The method of claim 1, wherein the construct comprises a nucleotide sequence not less than 90% identical to SEQ ID NO: 2.

14. The method of claim 13, wherein the construct comprises a nucleotide sequence not less than 95% identical to SEQ ID NO: 2.

15. The method of claim 14, wherein the construct comprises the sequence of SEQ ID NO: 2.

16. The method of claim 1, wherein the construct further comprises a terminator sequence, a self-replication sequence, or a secretory signal.

17. The method of claim 1, wherein the expression efficiency of the construct is higher than the expression efficiency of HGF cDNA or deleted variant HGF (dHGF) cDNA.

18. The method of claim 1, wherein the expression level of the construct is about 20- to 100-fold higher than the expression level of the HGF cDNA or dHGF cDNA.

[19. The method of claim 1, wherein the cell is a mammalian cell, a bacterial cell or a yeast cell.]

[20. The method of claim 19, wherein the cell is a mammalian cell.]

[21. The method of claim 20, wherein the transformation of said mammalian cell is *in vivo*.]

* * * * *